Acurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs. Vancomycin and Fidaxomicin (Standards of Care) in Clostridioides difficile and Vancomycin-Resistant Enterococcus Co-Cultures

Acurx Pharmaceuticals Inc (ACXP) (Q2 2026) Earnings Call Highlights: FDA Signals Potential ...

Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat

Acurx Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update

Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics

Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor Antibiotics

FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection

Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile Infection

Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update